This study evaluated the prognostic impact of obesity in multiple myeloma ith 18F-FDG PET CT guided measurement of total ab dominal adipose tissue (TAAT) radiodensity, subcutaneous adipose tissue (SAT) and visceral adipose tissue ( AT) glucose Three hundred and eight patients ho have been diagnosed ith multiple myeloma and received chemotherapy in our hospital from 2011 to 2021 ere retrospectively evaluated. 18F-FDG PET CT scans at diagnosis ere used to calculate TAAT, AT and SAT maxi mum standardized uptake value (SU max) and these values ere evaluated for their effect on adverse prognostic factors, sion free (PFS) and overall survival (OS). After being evaluated for exclusion criteria, 94 patients ere included for the -uptake. tissue volume greater than 6658 cc, TAAT radiodensity less than-97 associated ith significantly increased the OS (p 0.040, p 0.001 and p 0.001, respectively). E ach step of orsening of treatment, no transplantation, SAT SU max more than 0.3 ere associated ith reduced PFS in patients ith myeloma (p 0.004, p 0.001 and p 0.005 respectively). Similarly, each step of orsening response to treatment, total protein greater than 6.6 increase in stage, no transplantation, TAAT radiodensity more than-97 HU ere associated ith significantly reduced OS (p p 0.009, p 0.001, p 0.028 and p 0.001 respectively). SAT SU max and TAAT radiodensity are t o independent prognostic marker that influences PFS and OS respectively. - progres-study. Adipose Hounsfield units (HU), and SAT SU max of 0.3 or lo er ere response to mg dl, each 0.003,